CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 1,948 enrolled
Drug / intervention
ACURATE neo2™ Transfemoral TAVR System +3 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03735667
NCT03735667N/AActive

ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR

Boston Scientific Corporation·interventional·Posted Nov 8, 2018·Updated May 4, 2026

In Brief

A clinical study evaluating ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, and 2 other interventions for Aortic Stenosis. Active but no longer recruiting, targeting 1,948 participants across 75 sites in 2 countries.

Detailed Summary

To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR. As of 28-May-2025, Boston Scientific Corporation (BSC) announced the voluntary global discontinuation of the ACURATE product platform, including both the ACURATE neo2 and ACURATE Prime Aortic Valve Systems. BSC will no longer pursue regulatory approval for the device in the U.S. or other unapproved geographies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Stenosis
CountriesCanada, United States
Collaborators--

Timeline

N/AActive
20192020202120222023202420252026202720282029
First PostedNov 8, 2018
Enrollment StartJun 10, 2019
Primary CompletionJun 14, 2024
Study CompletionSep 1, 2029
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.6 years ago

Interventions

ACURATE neo2™ Transfemoral TAVR Systemdevice

ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).

Medtronic CoreValve TAVR Systemdevice

Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).

Edwards SAPIEN 3 TAVR Systemdevice

Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)

ACURATE Prime™ Transfemoral TAVR System XLdevice

ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).